Please login to the form below

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again

Latest news

Genfit scraps phase 3 trial of experimental NASH drug

Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in
Zydus Cadila scores first ever NASH approval, in India

Another potential treatment for NASH – from Intercept – is currently under review with the US Food and Drug Administration (FDA). ... additional information provided in response to FDA requests,” Intercept wrote in the filing at the time.
FDA delays decision on Intercept's NASH drug by three months

Intercept confirmed the delay in a filing with the US Securities &Exchange Commission last week. ... additional information provided in response to FDA requests,” Intercept wrote in the filing.
Boehringer bolsters NASH pipeline with Enleofen link-up

Meanwhile, Intercept Pharma’s obeticholic acid (OCA) is under priority review at the FDA for the treatment of liver fibrosis due to NASH, and could become the first drug to treat
Provention Bio wins PRIME designation for type 1 diabetes prevention drug

1R inhibition intercepts the migration of inflammatory cells to the gut.

More from news
Approximately 10 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Simon Doyle joins STEM

Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
Glenn Sblendorio to retire as president of The Medicines Company

He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Blog: 5 ingredients: Multichannel marketing, simplified

Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
Market Insights Can Deliver a Better Patient Experience

Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...